Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.
It is a $31.1B healthcare company. Revenue grew 95.1% over the last year, and it keeps 17¢ of every dollar of sales as profit. It trades at 38.5× earnings — near the lowest of its own history.
- Website
- alnylam.com
- Location
- Cambridge, MA
- Employees
- 2 500
- Sector
- Healthcare
- Founded
- 2002
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Valuation and Moat lag behind.
Valuation47
- P/E vs own history8th pct · 25/25
- FCF yield2.6% · 5/25
- P/S6.5x · 12/25
- EV/EBITDA31.8x · 5/25
Growth50
- Revenue CAGR44.8% · 25/25
- Net income CAGRn/a · 0/25
- EPS CAGR ~5Yn/a · 0/25
- Fwd implied growth37.6% · 25/25
Profitability65
- ROICn/a · 0/25
- ROE93.6% · 25/25
- Net margin16.8% · 20/25
- Operating margin19.9% · 20/25
Health60
- Altman Z4.40 · 25/25
- Current ratio3.05 · 25/25
- Interest coverage3.3x · 10/25
- Net cash / debtn/a · 0/25
Quality57
- Piotroski F6/9 · 15/25
- Beneish M-2.32 · 20/25
- FCF conversion98% · 22/25
- Margin stabilityσ 292.9% · 0/25
Moat25
- ROIC >12% years0/3 yrs · 0/25
- Median gross margin86.4% · 25/25
- FCF-positive years2/10 yrs · 0/25
- Worst-year net marginworst -1016.6% · 0/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2025FinancialTurned profitable$314M net income after a loss year
- FY2025FinancialBest year on record$314M net income
- FY2022FinancialRevenue crossed $1B$1.04B for the year
- 2016AcquisitionThe company purchased land in Norton, Massachusetts to build a manufacturing facility
- 2014AcquisitionSanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's…
- 2003AcquisitionThe firm merged with the German pharmaceutical company, Ribopharma AG
- 2002FoundedThe company was founded in 2002 and is headquartered in Cambridge, Massachusetts
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (79.7%)
- Revenue growing 95.1% year over year
- Strong cash conversion — FCF is 16.5% of revenue
- Altman Z-Score 4.40 — low bankruptcy-risk zone
Watch-outs
- Loss-making in 9 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+95.1% YoY
- Profitable — makes more than it spends$808M TTM
- Profit growing — earnings are higher than last year+212.8% YoY
- Generates cash — cash left after running and investing$794M TTM
- Debt under control — could handle its obligationscurrent ratio 3.05
- Established company — not a micro-cap — lower blow-up risk$31.1B market cap
- Not printing shares — share count not ballooning — you keep your slice+13.7% shares over ~5y
- Proven track record — years of profitability behind it1/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 4.4 — safe
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 38.5
Peer comparisonAlnylam Pharmaceuticals, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| ALNY this company | $31.1B | 38.5 | +95.1% | 16.8% | Strong |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: ALNY vs LLY · ALNY vs JNJ · ALNY vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/ALNY
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of ALNY on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $232.60 · market cap $31.1B.